(Q27681399)
Statements
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer (English)
0 references
26 July 2012
0 references
55
0 references
14
0 references
6523-40
0 references